)
Visual
test
Sanofi India
Sanofi India (500674) investor relations material
Sanofi India Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary29 Oct, 2025
Executive summary
Underwent a major business transformation in 2025, focusing on diabetes and insulin, modernizing the business model for sustainable, profitable growth, and shifting legacy cardiovascular, CNS, and oral antidiabetic drugs to a partnership model.
Digitally empowered teams and adopted AI-driven tools to enhance customer centricity, operational efficiency, and market reach, especially in Tier II/III cities.
Strategic focus on innovative diabetes products like Toujeo and Soliqua, with market expansion initiatives and public sector engagement.
Unaudited financial statements for the quarter and nine months ended September 30, 2025, were approved by the Board on October 29, 2025.
Interim dividend of ₹75 per equity share declared for 2025, with a record date of November 7, 2025.
Financial highlights
Diabetes segment grew 4% YTD September 2025 and 5% quarter-over-quarter; domestic sales grew 3% YTD and 2% in Q3 2025.
Export sales declined 35% YTD and 45% in Q3 2025 year-over-year, impacted by Ankleshwar site divestment and regulatory delays, but new markets like Russia and South Africa are being targeted.
Operating expenses as a percentage of net sales improved to 22% in Q3 2025 from 26% in Q1 2025.
Net sales margin and PBT margin improved to 29% in Q3 2025, with profit before tax up 15% year-over-year.
Nine-month profit from continuing operations was ₹2,650 million, up from ₹2,224 million year-over-year.
Outlook and guidance
Focus remains on accelerating diabetes performance, especially with Toujeo and Soliqua, leveraging AI for future growth, and prioritizing organic growth from the current portfolio.
Margins expected to remain stable or improve due to ongoing OpEx optimization and operational excellence.
No major new product launches expected in 2026.
Assess export recovery plan effectiveness
Generic semaglutide impact on insulin sales?
Global product launch strategy for India?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebPGIL
Strong 9MFY26 growth with 13.2% higher revenue, margin gains, and upgraded credit ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 7 FebSBIN
Q3 FY26 net profit reached ₹21,028.15 crore, driven by robust income and strategic divestments. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026.
Next Sanofi India earnings date
Q4 202527 Feb, 2026
Sanofi India
Next Sanofi India earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Sanofi India Limited is an Indian pharmaceutical company engaged in the manufacturing and marketing of prescription medicines and consumer healthcare products. It offers treatments in therapeutic areas such as diabetes, cardiovascular diseases, central nervous system disorders, and dermatology. The company is a subsidiary of global healthcare company Sanofi. It is headquartered in Mumbai, India, and its shares are listed on the BSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage